Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Mar 1;17(3):e0264773. doi: 10.1371/journal.pone.0264773

Proline-based solution maintains cell viability and stemness of canine adipose-derived mesenchymal stem cells after hypothermic storage

Pongsatorn Horcharoensuk 1, Sunantha Yang-en 1, Amarin Narkwichean 2, Ruttachuk Rungsiwiwut 1,*
Editor: Nazmul Haque3
PMCID: PMC8887718  PMID: 35231072

Abstract

Transportation of mesenchymal stem cells (MSCs) under hypothermic conditions in 0.9% normal saline solution (NSS) might increase cell death and alter the stemness of MSCs. The present study aimed to evaluate the effect of proline-based solution (PL-BS) on cell viability and the stemness of newly established canine adipose-derived mesenchymal stem cells (cAD-MSCs) under hypothermic conditions. Characterized cAD-MSCs were stored in 1, 10, and 100 mM PL-BS or NSS at 4°C for 6, 9, and 12 hours prior to an evaluation. The results demonstrated that storage in 1 mM PL-BS for 6 hours decreased cell apoptosis and proliferation ability, but improved cell viability and mitochondrial membrane potential. cAD-MSCs maintained their high expression of CD44 and CD90, but had a low expression of CD34 and MHC class II. Trilineage differentiation ability of cAD-MSCs was not affected by storage in 1 mM PL-BS. Gene expression analysis demonstrated that immunomodulatory genes, including IDO, HGF, PGE-2, and IL-6, were upregulated in cAD-MSCs stored in 1 mM PL-BS. In conclusion, PL-BS can be effectively applied for storing cAD-MSCs under hypothermic conditions. These findings provide a new solution for effective handling of cAD-MSCs which might be promising for clinical applications.

Introduction

Mesenchymal stem cells (MSCs) are multipotent cells which are able to regenerate themselves and differentiate into many cell types [1]. The therapeutic potential of MSCs, especially in regenerative medicine, is widely recognized due to their stemness [2], including capacity to migrate to injured sites, immunomodulation, anti-inflammation, anti-apoptosis, neo-angiogenesis, antimicrobial activity, and tissue regeneration. Recently, clinical trials of MSC therapies have been performed to treat several diseases, such as cardiovascular, neurological, immune-mediated, and traumatic-related diseases, and so forth. The vast majority of the clinical trials have been in phase 2 (61.0%), while others have been in phases 1 (30.8%), 3 (7.5%), and 4 (0.7%), respectively. In addition, those trials have been conducted in 51 countries globally, especially in China (25.25%), United States of America (20.6%), and Spain (7.67%) [3]. Based on cell therapy, the workflow consists of three major complicated processes. The first is an extraction of MSCs from donors; it is required that this step is performed at the cell processing center. The most common sources of MSCs in adult humans are bone marrow, adipose tissues, and peripheral blood, respectively [4]. Meanwhile, those in companion animals include adipose tissues and bone marrow. In addition, adipose tissues can be easily and practically harvested from domesticated dogs and cats by a routine sterilization procedure [5]. Second, it is required that MSCs are isolated, cultured, multiplied, and preserved under freezing conditions for long-term storage. Third, the cells have to be defrosted and subsequently cultured prior to transplantation. Finally, the collected and processed cells require transport solutions for shipment before they are applied to the patients [6].

The transportation time of stem cell packages varies depending on the distance between the cell processing center and the hospital. In general, short-term transportation requires temperature control, either at a severely hypothermic state (2–8°C) or at room temperature (25°C). On the contrary, preservation for long-term transportation needs a frozen state (below 0°C) so that the cryoprotectant works to prevent cell death [7, 8]. Previously, effects of storage temperature on MSCs have been widely studied. Gálvez-Martín and colleagues, who were studying the influence of storage temperature on human adipose-derived stem cells (hADSCs) kept in different storage solutions at 4°C, 25°C, and 37°C for up to 60 hours, demonstrated that hADSCs are able to maintain the highest viability at 4°C, when compared to viability at 25°C and 37°C, respectively [9]. Gniadek and colleagues demonstrated that peripheral blood-derived mononuclear cells (MNCs) preserved in 5% human serum albumin solution and Hypothermosol FRS at 4°C possess higher cell viability than at 25°C [10]. These results emphasized the importance of suitable solutions for maintaining stem cell viability when stored at 4°C. For short-term storage and cell transportation, a number of solutions can be applied as the hypothermic solution, such as 0.9% normal saline solution (NSS), Ringer solution, Plasma-Lyte A, phosphate-buffered saline (PBS), platelet-rich plasma, etc. In human clinical trials, 0.9% NSS has been used for short-term transportation of human MSCs [11]. However, negative effects of NSS on cell viability and MSC stemness have been reported. For instance, Chen and colleagues demonstrated that storing human umbilical cord mesenchymal stem cells (hUC-MSCs) in NSS at 4°C significantly decreases cell viability and adhesion capacity in a time-dependent manner but increases the population doubling time. It can be implied that hUC-MSCs cannot be recovered efficiently after being stored in hypothermic conditions and may lose their proliferation ability after transplantation into the patients. Sohn and colleagues reported that storing human bone marrow stem cells (hBMSCs) in NSS at 4°C decreases their viability, level of colony-forming units, and trilineage differentiation ability. This suggests that short-term preservation of MSCs in NSS at 4°C may not be an effective method as a decrease in cell proliferation and differentiation capacity occurs [12, 13].

Therefore, the objective of the present study was to improve the efficiency of NSS as a solution for short-term storage, under hypothermic conditions, of canine adipose-derived mesenchymal stem cells (cAD-MSCs). To date, there have been no reports about using proline, a novel cryoprotective agent, as a supplement for cell transportation solutions. Thus, proline would be a great candidate for studying protective effects during hypothermic conditions.

Materials and methods

Animal use

The protocols of animal use in the present study were approved by the Institutional Ethics Committee of Srinakharinwirot University (COA/AE-017-2563). Subcutaneous or periovarian fat samples were collected during routine castration or ovariohysterectomy procedures from three dogs at iVET animal hospital. The inclusion criteria for the dogs were as follows: (1) age between one and three years, (2) complete vaccination based on AAHA guidelines, (3) ectoparasite prevention three months prior to surgery, and (4) a normal blood profile.

Experimental designs

In the present study, samples were completely randomized and divided into two parts, which were (1) isolation and characterization of cAD-MSCs and (2) evaluation of the effect of proline-based solution (PL-BS) on cell viability, mitochondrial membrane potential (MMP), proliferation ability, specific surface markers, trilineage differentiation, and immunomodulatory properties of cAD-MSCs after storage in a hypothermic state.

In the first part, cAD-MSCs were isolated from fat tissues of the dogs and evaluated for stemness. In the second part, the cAD-MSCs were divided into three groups: non-storage control, hypothermic-storage in NSS, and hypothermic-storage in proline-based solution (PL-BS). L-proline (Catalog number P0380, Sigma-Aldrich®, USA) was prepared in NSS at concentrations of 1, 10, and 100 mM. The harvested cAD-MSCs in groups 2 and 3 were stored at a concentration of 1x106 cells per 1 ml of storage solution and kept at 4°C for 6, 9, and 12 hours in order to mimic the hypothermic transportation conditions. cAD-MSCs growing at 37°C, 5% CO2, were used as the non-storage control group.

Isolation and expansion of canine adipose-derived mesenchymal stem cells

Adipose tissues were isolated from two male dogs and one female dog, kept in sterile containers filled with sterile NSS, and transferred to the stem cell laboratory within two hours. Fat tissues were washed in 70% ethanol, followed by PBS. The vessels were removed, and the tissues were minced into small pieces (<1 mm.) before tissue digestion was performed by adding 0.5 mg/ml collagenase type IV in PBS (Catalog number 17104019, Gibco, Thermo Fisher Scientific, USA) and incubating for 1 hour at 37°C, 5% CO2. After that, the enzyme activity was neutralized with a culture medium containing 10% fetal bovine serum (FBS, Catalog number S1810, Biowest, USA). Afterwards, the cell suspension was filtered through a 40 μm cell strainer (Catalog number 93040, SPL Life Sciences, South Korea) and centrifuged at 2,300 rpm for 5 minutes. Finally, the supernatant was discarded and cell pellets were resuspended in the culture medium consisting of MEM alpha modification (Catalog number SH30265.02, Hyclone, USA), 10%FBS, 1% penicillin/streptomycin (Catalog number 03-031-1B, Biological Industries, Israel), and 10 ng/ml human fibroblast growth factor basic recombinant protein (FGF-2/bFGF, Catalog number PHG0026, Invitrogen, USA). The cell suspension was seeded onto a culture plate and incubated at 37°C, 5% CO2, and the culture medium was replaced every other day. These cells were designated as passage 0 (P0). The expansion procedure was performed when the cells reached 80–90% confluence. In brief, the culture medium was discarded and the adherent cells were washed with PBS to remove the remaining residues. Cell dissociation was performed using 0.05% trypsin/EDTA (Catalog number 03-051-5B, Biological Industries, Israel) and incubating at 37°C, 5% CO2 for 5 minutes. After incubation, the cells were gently dispersed using pressure from a pipette, and enzyme activity was neutralized by adding a culture medium containing 10% FBS. The cell suspension was centrifuged at 2,300 rpm for 5 minutes, and subsequently, the supernatant was discarded and the cell pellet was resuspended with the culture medium. Eventually, the cell suspension was seeded onto the culture plate, and these cells were designated as passage 1 (P1). The expansion protocol was repeated to multiply the cell number. Cells from passages 3 to 5 (P3-P5) were used in the experiments.

Cell viability and apoptotic/necrotic fraction assay

Both the non-stored and stored cAD-MSCs were evaluated for the percentage of live cells and the apoptotic/necrotic cell fraction using ApoScreen® Annexin V Apoptosis Kit-FITC (Catalog number 10010–02, SouthernBiotech, USA). In brief, the cells were collected, washed with PBS, and resuspended in a 1x binding buffer. Annexin V-FITC antibody was added into the cell suspension, which was then incubated at 4°C for 15 minutes; after that, propidium iodide (PI) was added. Live and apoptotic/necrotic cells were gated to 1x104 cells and then analyzed by Guava easyCyte 5HT Flow Cytometer (Millipore, USA).

Mitochondrial membrane potential assay

The cAD-MSCs were evaluated for MMP using the TMRE-Mitochondrial Membrane Potential Assay Kit (Catalog number ab113852, Abcam, UK). In brief, 250 nM TMRE was added into 1x105 cells/well of both non-stored and stored cAD-MSCs in a suspension condition; the cell suspension was incubated for 15 minutes and then washed twice with 0.2% BSA in PBS prior to being loaded into a 96 well-plate and evaluated for fluorescence intensity using a microplate reader (Synergy HT, BIO-TEK, USA) with Ex/Em = 549/575 nm.

Proliferation assay

The non-stored and stored cAD-MSCs were collected, washed, and seeded back into 96 well-plates at a concentration of 1x104 cells/well, and incubated with 5%CO2, at 37°C for 24 hours. Cell proliferation was evaluated using Cell Proliferation Kit I (MTT, Catalog number 11465007001, Roche Diagnostics, Germany). In brief, 10 μl of MTT solution I was added to the cell culture plate and incubated for 4 hours. Therefore, 100 μl of MTT solution II was added to the cell culture plate and cultured for 24 hours. The absorbance was measured by using a microplate reader (HiPo MPP-96 Microplate Photometer, Biosan, Latvia) at 550 nm.

Expression of specific surface antigens

An analysis of specific surface antigens for MSCs, including CD44, CD90, CD34, and MHC class II, was performed by flow cytometry. In brief, the cell pellets of non-stored and stored cAD-MSCs were washed with PBS and resuspended in cold flow buffer (PBS with 5% bovine serum albumin (BSA), Catalog number 03-010-1B, Biological Industries, Israel) at a concentration of 5x 105 cells/tube stained with conjugated antibody, for 30 minutes, and kept at 4°C with light protection. After incubation, the cell suspension was washed once with a cold flow buffer and resuspended with 400 μl of cold flow buffer. Finally, the cell surface antigens were gated to 1x104 cells and then analyzed by flow cytometry. The antibodies used in the present study were anti-CD44-FITC Monoclonal Antibody (Catalog number 11-5440-42, Invitrogen, Thermo Scientific, USA), anti-MHC class II-FITC (Catalog number 11-5909-42, Invitrogen), anti-CD34-PE (Catalog number MA1-81855, Invitrogen), and anti-CD90-PE (Catalog number 12-5900-42, Invitrogen).

Trilineage differentiation assay

The non-stored and stored cAD-MSCs were both induced for differentiation into three lineages, which were adipogenic, chondrogenic, and osteogenic lineages, in order to evaluate the differentiation potential. Adipogenic differentiation was adapted from previous studies [14, 15] and supplemented by Chemicon® Mesenchymal Adipogenesis Kit (Catalog number SCR020, Sigma-Aldrich®, USA). Adipogenic induction medium consisted of high-glucose DMEM, 15% rabbit serum, 1 μM dexamethasone, 10 μg/ml insulin, 200 μM indomethacin, 0.5 mM isobutyl-methylxanthine (IBMX), and 1% penicillin/streptomycin. The medium was changed every 1–2 days. On day 21, cells were fixed with 4% paraformaldehyde (PFA), washed with PBS, and stained with oil red O solution. ChondroMAX differentiation medium (Catalog number SCM123, Sigma-Aldrich®, USA) was used for chondrogenic differentiation. The chondrogenic differentiation medium was changed every 1–2 days. On day 21, cells were fixed with 4% PFA, stained, and washed with distilled water containing alcian blue solution (Catalog number B8438, Sigma-Aldrich®, USA). StemPro Osteogenesis Differentiation Kit (Catalog number A1007201, Gibco, USA) was used for osteogenic differentiation. The osteogenic differentiation medium was changed every 3–4 days. On day 21, cells were fixed with 4% PFA, washed with distilled water, and stained with alizarin red S solution (Catalog number A5533, Sigma-Aldrich®, USA).

Immunomodulatory gene expression

Total RNA was extracted from non-stored and stored cAD-MSCs by using the GeneJET RNA Purification Kit (Catalog number K0731, Thermo Scientific, USA) and following the manufacturer’s protocol. Total RNA concentration was quantified by Nanodrop 2000c spectrophotometer (Thermo Scientific, USA). Total RNA was reversely transcribed for cDNA synthesis by using the Superscript III Enzyme Reverse Transcriptase kit (Catalog number 18080093, Invitrogen, Thermo Scientific, USA). Gene expression was evaluated by quantitative polymerase chain reaction (qPCR) using the C1000 TouchTM thermal cycler and CFX96 Real-Time PCR Detection System (Bio-Rad, USA). The reactions were performed by using iTaq Universal SYBR® Green Supermix (Catalog number 1725120, Bio-Rad, USA) with immunomodulatory genes including indoleamine 2, 3-dioxygenase (IDO), hepatocyte growth factor (HGF), prostaglandin E2 (PGE-2), and interleukin-6 (IL-6), and the target genes of interest. The 18S gene, a housekeeping gene, served as the control. The primer sequences, based on the previous study, are displayed in S1 Table. The reaction conditions consisted of 40 cycles at a pre-denaturation temperature of 95°C for 30 seconds, denaturation temperature of 95°C for 5 seconds, and annealing/extension temperature of 60°C for 30 seconds, respectively. The gene expression results were quantified by normalization using the 2−ΔΔCT method.

Statistical analysis

The experiments were performed in triplicate, and the data were presented as mean ± standard deviation (SD). Data were analyzed using GraphPad Prism program version 9.2.0 (GraphPad Software, Inc., USA). Differences among groups were assessed by analysis of variance (ANOVA). Post-hoc multiple comparisons were made by the Tukey–Kramer test. Statistical significance was accepted at a p-value < 0.05.

Results

Isolation and characterization of canine adipose-derived stem cells

Morphology

After 2 days of isolation, the culture dishes were composed of several adherent cells with different morphology, including fibroblast-like or epithelial-like shapes. After 7 days, cells became more homogenous and the dominant cells were fibroblast-like. Cells reached 80–90% confluence at 14 days of isolation. In addition, the morphology of the three cell lines isolated from different donors was not notably different from one another (S1 Fig).

Expression of specific surface antigens

Based on flow cytometry, the isolated cells expressed CD44 (97.10±1.71%), CD90 (96.88±0.50%), CD34 (2.28±0.53%), and MHC class II (1.24±0.86%), as shown in Fig 1. In addition, a notable difference in expression of specific surface antigens was not observed among the three cell lines isolated from different donors (S2 Fig).

Fig 1. Expression of specific surface antigens of canine adipose-derived mesenchymal stem cells in different conditions.

Fig 1

The stored cAD-MSCs highly expressed CD44 and CD90 but were deprived of CD34 and MHC class II, which was similar to the control group.

Trilineage differentiation

The isolated cells exhibited differentiation potential, which could be divided into adipogenic, chondrogenic, and osteogenic lineages, as illustrated in Fig 2. The red-colored fat droplets were seen in adipocytes. The chondrocytes were observed as blue-stained spheroidal cells. The calcium-deposited osteocytes were stained red. All three lines of cAD-MSCs exhibited osteogenic differentiation potential. In addition, the differences among three lines were not distinct (S3 Fig).

Fig 2. The effect of a hypothermic solution on trilineage differentiation of canine adipose-derived mesenchymal stem cells.

Fig 2

The stored cAD-MSCs were able to differentiate into adipocytes, chondrocytes, and osteocytes. The red-stained fat droplets in adipocytes indicate adipogenic differentiation potential. The blue color indicates that chondrocytes are capable of producing proteoglycan in the extracellular matrix. The osteocytes that had accumulated calcium are shown in red color. Scale bars = 300 μm.

Effect of proline-based solution (PL-BS) on cell viability, proliferation ability, mitochondrial membrane potential (MMP) and stemness of cAD-MSCs after storage in a hypothermic state

The 1 mM PL-BS decreased cell death during hypothermic storage

According to the flow cytometry results, the maintenance of cAD-MSCs under hypothermic conditions dramatically increased levels of apoptotic and necrotic cells in a time-dependent manner (Fig 3A and S4 Fig). However, storing cAD-MSCs in 1 mM PL-BS for 6 hours significantly improved cell viability by inhibiting early apoptosis and necrosis in comparison with other concentrations of both PL-BS and NSS, as shown in Fig 3A and 3B. Notably, only at 6 hours after storage was the number of live cells in 1 mM PL-BS (90.71±1.20%) significantly higher than that in NSS (77.19±2.19%, p<0.01). Besides, the cells in 1 mM PL-BS (1.43±1.10%) had a significantly lower number of early apoptotic cells than those in NSS (9.91±4.97%, p<0.05), as displayed in Fig 3C.

Fig 3. The effect of a hypothermic solution on cell viability and apoptotic/necrotic fraction.

Fig 3

(A) The cAD-MSCs were stored in hypothermic solutions at concentrations of 1, 10, and 100 mM PL-BS or NSS for up to 6, 9, and 12 hours. (B) At 6 hours of hypothermic storage, the percentage of cAD-MSCs which had survived in 1 mM PL-BS was significantly higher than that in NSS (p<0.01). (C) The level of early apoptotic cells at 6 hours of hypothermic storage in 1 mM PL-BS was significantly lower than that in NSS (p<0.05). Remark symbols: Asterisk means values were significantly different from the NSS group; * = p<0.05 and ** = p<0.01. The lowercase letters a, b, c, and d above the bar indicate significant difference from the control group; a = p<0.05, b = p<0.01, c = p<0.001, and d = p<0.0001.

The 1 mM PL-BS preserved MMP during hypothermic storage

MMP values were measured with a spectrophotometer, and are shown in Fig 4A. At 6 hours of storage, the cAD-MSCs stored in NSS (7236.25±552.61 au., p<0.0001) and 1 mM PL-BS (8243.50±290.11 au., p<0.001) showed a significant decrease in MMP compared to non-stored cells. However, the MMP of cAD-MSCs stored in 1 mM PL-BS was significantly higher than that of cAD-MSCs stored in NSS (p<0.05).

Fig 4. Comparison of mitochondrial membrane potential and proliferation of canine adipose-derived mesenchymal stem cells in different conditions.

Fig 4

(A) Based on TMRE assay, the mitochondrial membrane potential (MMP) of cAD-MSCs stored in both NSS and 1 mM PL-BS for 6 hours, was significantly lower than that in the control group, (p<0.0001 and p<0.001, respectively). However, the MMP of cAD-MSCs stored in 1 mM PL-BS was significantly higher than that in NSS (p<0.05). (B) According to MTT assay, the proliferation rate of cAD-MSCs stored in NSS or 1 mM PL-BS was significantly lower than that in non-storage cells (p<0.01 and p<0.001, respectively). Remark symbols; Asterisk represents a significant difference (p<0.05). The lowercase letters b, c, and d indicate significant difference from the control group; b = p<0.01, c = p<0.001, and d = p<0.0001.

Hypothermic storage decreased the proliferation ability of canine adipose-derived mesenchymal stem cells

MTT assay revealed the proliferation rate of adherent cells, as shown in Fig 4B. At 6 hours of hypothermic storage, cAD-MSCs stored in NSS (0.3170±0.0095 au.) and 1 mM PL-BS (0.3288±0.0076 au.) showed a significant decrease in proliferation rate in comparison with that of non-stored cells (0.4616±0.0505 au., p<0.01). Moreover, no significant difference in proliferation rate was observed between storage in NSS and storage in 1 mM PL-BS.

The hypothermic conditions did not negatively affect the expression of specific surface antigens

An analysis using flow cytometry exhibited that there was no apparent difference in the expressions of CD44, CD90, CD34, and MHC class II between the control and cells stored in NSS and 1 mM PL-BS (Fig 1 and S2 Fig).

The hypothermic solutions did not alter the differentiation potential of canine adipose-derived mesenchymal stem cells

After fixing and staining differentiated cells with specific dyes, cAD-MSCs stored in NSS or 1 mM PL-BS maintained their trilineage differentiation ability, as shown in Fig 2. The differentiation abilities were confirmed by the positive staining of oil red O, alcian blue, and alizarin red S for adipogenic, chondrogenic and osteogenic differentiation, respectively. In addition, there was no obvious difference in differentiation ability among cAD-MSC lines derived from different donors (S3 Fig).

The hypothermic solutions affected the expression of immunomodulatory genes in canine adipose-derived mesenchymal stem cells

An analysis of gene expression with real-time RT-PCR indicated that the expressions of IDO and IL-6 were significantly upregulated in cAD-MSCs stored in NSS and 1 mM PL-BS, compared to non-stored cAD-MSCs (p<0.001), as demonstrated in Fig 5 and S2 Table. The expression level of HGF in cAD-MSCs stored in 1 mM PL-BS was significantly higher than that of cAD-MSCs stored in NSS and non-stored cells (p<0.05). In addition, the expression level of PGE-2 from cAD-MSCs stored in 1 mM PL-BS was lower than that of cAD-MSCs stored in NSS (p<0.05).

Fig 5. Effect of a hypothermic solution on the expression of immunomodulatory genes.

Fig 5

Based on real-time RT-PCR, the level of IDO and IL-6 expression significantly increased when cAD-MSCs were stored in NSS or 1 mM PL-BS (p<0.001). The expression level of HGF significantly increased in cAD-MSCs stored in 1 mM PL-BS compared to non-stored cells (p<0.05). The PGE-2 expression level in NSS stored-cAD-MSCs was significantly higher than that in non-stored cells (p<0.05). Remark symbols; IDO = indoleamine 2, 3-dioxygenase, IL-6 = interleukin-6, HGF = hepatocyte growth factor, and PGE-2 = prostaglandin E2; Lowercase letters above the bars indicate a significant difference compared to the control group; a = p<0.05, c = p<0.001, and d = p<0.0001.

Discussion

Mesenchymal stem cell therapy is promising for patients affected by several illnesses, such as degenerative, immune-mediated, and metabolic diseases [16]. The minimal criteria of MSC characteristics proposed by the International Society for Cell and Gene Therapy (ISCT) include (1) adherence to cell culture plates, (2) expression of specific surface antigens, such as CD73, CD90, and CD105, above 95% but expression of others, such as CD34, CD45, or HLA-II, lower than 2%, and (3) differentiation into three lineages, which are adipogenic, chondrogenic, and osteogenic lineage [17]. In veterinary medicine, one of the common sources for derivation of MSCs in dogs (Canidae) is adipose tissues. Therefore, cAD-MSCs have been widely studied both in basic and clinical research [5]. In the present study, newly derived cAD-MSCs exhibited fibroblast-like shapes, culture-plate-adhesion capacity, and trilineage differentiation, which were similar to characteristics of human MSCs [14, 15, 18]. Besides, cAD-MSCs in our study had CD44 and CD90 expression of more than 95% but were deprived of CD34 and MHC class II expression, similar to a number of the previous reports [1921].

According to the United States Food and Drug Administration (US FDA) recommendations, the viability of stem cell products prior to clinical application should be greater than 70% [22]. Interestingly, approximately 70% of the stem cell clinical trials used NSS, which is approved by the US FDA as a cell-transportation solution [11, 23]. It is generally accepted and has been proven that prolonged storage of MSCs at 4°C, or under the physiological temperature, provokes cell damage and death. Several studies have been performed on human MSCs and contradictory results have been reported. For example, Pal and colleagues demonstrated that although the storage of human BMSCs in NSS at 4°C does not alter their differentiation capacity, the cells should be used within 6 hours in order to avoid cell death [24]. Chen and colleagues suggested that hUC-MSCs can be stored in NSS at 4°C for up to 6 hours without changing the expression of surface antigens, differentiation ability and immunomodulatory property of the cells. However, negative effects, such as a decrease in cell proliferation and adhesion capacity, could be consequences [12]. In contrast, the study of Sohn and colleagues demonstrated that NSS influences the differentiation ability and colony-forming units of hBMSCs in a time-dependent manner [13]. Nevertheless, the effect of NSS may vary depending on the source of the MSCs. Nofianti and colleagues’ results demonstrated that hADSCs can maintain a cell viability of more than 70% after being stored in NSS for up to 48 hours; however, their proliferation rate significantly decreased after storage for 24 hours. The authors also suggested that hADSCs be applied for cell therapy within 24 hours [25]. Ra and colleagues reported that hADSCs can be stored in NSS up to 72 hours without changes in surface marker antigens [26]. Unfortunately, the results from Wu and colleagues showed that hADSCs cannot maintain a cell viability of over 70% in NSS at 4°C [27]. Although many studies have demonstrated that storing the cells in NSS at 4°C decreases cell viability in a time-dependent manner and varies according to the source of the cells, information regarding canine MSCs is still lacking. Therefore, NSS was selected as a basic solution for handling cAD-MSCs during storage in hypothermic conditions in the present study. The current study confirmed that NSS efficiently maintained cAD-MSC viability at 4°C for 6–9 hours. When the NSS was supplemented with 1 mM of proline, the early apoptotic rate of the cAD-MSCs decreased. This resulted in an improvement of cAD-MSC viability. The protective effect of proline on early apoptosis and cell viability was clearly observed after storing the cAD-MSCs at 4°C for 6 hours. From these results, it might be implied that 1 mM of proline improved the capacity of NSS for handling cAD-MSCs under hypothermic conditions. Moreover, this solution did not affect expression of specific surface antigens and trilineage differentiation potential of cAD-MSCs. However, the proliferation ability of the stored cells was neither improved in NSS [12, 25] nor improved in 1 mM of supplemented proline, as demonstrated by the present study.

After being in hypothermic conditions, cells adapt themselves by reducing their metabolic rate due to decreased ATP production, oxygen demand, and energy storage degradation [28, 29]. Cell swelling can occur due to water retention resulting from the loss of K+ and diffusion into the cells of Na+ and Cl [30]. Moreover, that swelling can progressively occur when cells are stored in a solution with abundant Na+ and Cl-. Furthermore, prolonged storage time might decrease mitochondrial membrane potential, which induces mitochondrial depolarization contributing to mitochondrial dysfunction and subsequently progressive ROS production or oxidative stress, which finally results in cell death [3133].

Cryoprotective agents play a critical role in protecting the cells from freezing conditions (below 0°C). Besides, they can also protect the cells from cold temperatures (4°C) during cell transportation. Proline has been used as a cryoprotective agent for oocytes [34], human red blood cells [35], and human MSCs [36]. Proline is a natural non-toxic amino acid compound [37]. It has been identified as a penetrating cryoprotectant and acts as an osmoprotectant, helping balance osmotic pressure between cells and surrounding water during temperature stress or salt stress from Na+, K+, and Cl- [38]. In addition, proline stabilizes protein and macromolecules such as nucleic acid during cold stress [35, 39, 40]. Moreover, proline acts as an ROS scavenger during prolonged storage [41]. In the cells, proline metabolism helps increase glutathione production and maintain proper NADP+/NADPH level, which assists energy homeostasis [39]. From the results of the present study, it could be implied that proline might maintain mitochondrial integrity during environmental stress and subsequently inhibit cell death [42].

In spite of supportive maintenance of cAD-MSC viability, PL-BS improved the immunomodulation of cAD-MSCs. The present study demonstrated that genes encoding IDO and IL-6 were significantly upregulated in cAD-MSCs stored in PL-BS. Normally, IDO is expressed during immunosuppressive processes via inhibition of pro-inflammatory T-cells as well as induction of the regulatory T-cell population [43]. IL-6 is a pro- and anti-inflammatory cytokine which plays a major role in MSC proliferation and the immunosuppressive capacity of hBMSCs [44, 45]. Moreover, IL-6 maintains the stemness of hBMSCs via ERK1/2-dependent mechanisms [46]. Thus, the immunosuppressive impact of cAD-MSCs can be improved by using PL-BS during hypothermic transportation. The present study showed that despite the upregulation of IDO and IL-6 genes, the level of HGF expression was still upregulated after storing cAD-MSCs in PL-BS. It has been demonstrated that HGF reduces inflammatory Th1 cells via dendritic cells and stimulates regulatory T cells to produce immunosuppressive cytokines which are beneficial in the treatment of autoimmune diseases [47]. Besides, the upregulation of HGF expression in cAD-MSCs in the present study might positively correlate with an improvement of cell viability as HGF plays vital roles in delaying senescence, enhancing osteogenic differentiation potential, and preserving mitochondrial function [48]. PGE-2 regulates macrophages and dendritic cells as well as T- and B-cells; this subsequently involves pro- and anti-inflammatory processes [49]. In addition, PGE-2 promotes the migration of MSCs [50] and the downregulation of PGE-2, resulting in decreased immunomodulatory properties [51]. In the present study, the storage of cAD-MSCs in PL-BS slightly upregulated the expression of PGE-2, but this upregulation was not as high as that from cAD-MSCs stored in NSS. This might be due to the presence of negative feedback mechanisms of the storage cells in order to decrease the excessive amount of proline by lowering PGE-2 production [52, 53]. Therefore, the immunomodulatory capacity of cAD-MSCs can be improved by supplementation with TNF-α or IFN-γ during cultivation [54, 55].

Conclusions

Proline-based solution had a short-term protective effect on cAD-MSCs stored in hypothermic conditions. The supplementation of proline in NSS decreased levels of early apoptotic cells, maybe by preserving mitochondrial function, together with improving the cell viability and stemness of cAD-MSCs. Therefore, proline-based solution can be applied for short-term hypothermic transportation and might be beneficial in clinical application.

Supporting information

S1 Fig. Morphology of isolated canine adipose-derived mesenchymal stem cells.

After 2 days of isolation, the adherent cells with different morphology, including fibroblast-like or epithelial-like shapes, were observed in the culture dishes. After 7 days, the cells had become more homogenous and those with a fibroblast-like shape had become dominant. The cells reached 80–90% confluence at 14 days of isolation. There was no notable difference in cell morphology among the three cell lines that had been isolated from different donors. All figures were performed at 10x magnification. Scale bars = 300 μm.

(TIF)

S2 Fig. Expression of specific surface antigens of non-stored and stored canine adipose-derived mesenchymal stem cells was analyzed by flow cytometer.

The stored cells in NSS and 1 mM PL-BS highly expressed both CD44 and CD90 but were deprived of both CD34 and MHC class II. These results were not different from those of the control group.

(TIF)

S3 Fig. The effect of a hypothermic solution on trilineage differentiation.

The post-stored cAD-MSCs exhibited differentiability into three lineages, including adipocytes, chondrocytes, and osteocytes. The fat droplets in adipocytes are stained red, indicating adipogenic differentiation potential. The blue color points out that chondrocytes are capable of producing proteoglycan in the extracellular matrix. The osteocytes with calcium accumulation are shown in red. Scale bars = 300 μm.

(TIF)

S4 Fig. The effect of a hypothermic solution on cell viability and apoptotic/necrotic fraction.

The cAD-MSCs from two other donors decreased the number of live cells in a time-dependent manner during hypothermic conditions. However, storage of cAD-MSCs in 1 mM PL-BS for 6 hours considerably improved cell viability by decreasing early apoptosis and necrosis in comparison with storage in other concentrations of both PL-BS and NSS.

(TIF)

S1 Table. Sequence of primers used for evaluating the expression of immunomodulatory genes.

(DOCX)

S2 Table. The effect of a hypothermic solution on the expression of immunomodulatory genes.

The gene expression results were quantified by normalization using the 2-ΔΔCT method and are shown as Log2 values of relative gene expression.

(DOCX)

Acknowledgments

The authors would like to thank the veterinarian and staff of iVET animal hospital for providing all the samples for the present study.

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

Faculty of Medicine, Srinakharinwirot University (MED-GRAD-150; 511/2563 and MED-RES-200; 217/2563). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Shyam H, Singh SK, Kant R, Saxena SK. Mesenchymal stem cells in regenerative medicine: a new paradigm for degenerative bone diseases. Regen Med. 2017; 12(2): 111–114. doi: 10.2217/rme-2016-0162 [DOI] [PubMed] [Google Scholar]
  • 2.Alfaro MP, Saraswati S, Young PP. Molecular mediators of mesenchymal stem cell biology. Vitam Horm. 2011; 87: 39–59. doi: 10.1016/B978-0-12-386015-6.00023-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Rodríguez-Fuentes DE, Fernández-Garza LE, Samia-Meza JA, Barrera-Barrera SA, Caplan AI, Barrera-Saldaña HA. Mesenchymal Stem Cells Current Clinical Applications: A Systematic Review. Arch Med Res. 2021; 52(1): 93–101. doi: 10.1016/j.arcmed.2020.08.006 [DOI] [PubMed] [Google Scholar]
  • 4.Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011; 9: 12. doi: 10.1186/1478-811X-9-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Voga M, Adamic N, Vengust M, Majdic G. Stem Cells in Veterinary Medicine-Current State and Treatment Options. Front Vet Sci. 2020; 7: 278. doi: 10.3389/fvets.2020.00278 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Swioklo S, Connon CJ. Short-term Storage of Cells for Application in Cell-based Therapies. Connon CJ, editor. Bioprocessing for Cell Based Therapies. Wiley; 2017. pp. 187–210. [Google Scholar]
  • 7.Aoyama T. Transportation of Mesenchymal Stem Cells for Clinical Applications. Pham PC, Editor. Mesenchymal Stem Cells—Isolation, Characterization and Applications. IntechOpen; 2017, pp. 279–290. [Google Scholar]
  • 8.Zhang F, Ren H, Shao X, Zhuang C, Chen Y, Qi N. Preservation media, durations and cell concentrations of short-term storage affect key features of human adipose-derived mesenchymal stem cells for therapeutic application. PeerJ. 2017; 5: e3301. doi: 10.7717/peerj.3301 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Gálvez-Martín P, Hmadcha A, Soria B, Calpena-Campmany AC, Clares-Naveros B. Study of the stability of packaging and storage conditions of human mesenchymal stem cell for intra-arterial clinical application in patient with critical limb ischemia. Eur J Pharm Biopharm. 2014; 86(3): 459–468. doi: 10.1016/j.ejpb.2013.11.002 [DOI] [PubMed] [Google Scholar]
  • 10.Gniadek TJ, Garritsen HSP, Stroncek D, Szczepiorkowski ZM, McKenna DH; Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Optimal Storage Conditions for Apheresis Research (OSCAR): a Biomedical Excellence for Safer Transfusion (BEST) Collaborative study. Transfusion. 2018; 58(2): 461–469. doi: 10.1111/trf.14429 [DOI] [PubMed] [Google Scholar]
  • 11.Ścieżyńska A, Soszyńska M, Szpak P, Krześniak N, Malejczyk J, Kalaszczyńska I. Influence of Hypothermic Storage Fluids on Mesenchymal Stem Cell Stability: A Comprehensive Review and Personal Experience. Cells. 2021; 10(5): 1043. doi: 10.3390/cells10051043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Chen Y, Yu B, Xue G, Zhao J, Li RK, Liu Z, et al. Effects of storage solutions on the viability of human umbilical cord mesenchymal stem cells for transplantation. Cell Transplant. 2013; 22(6): 1075–1086. doi: 10.3727/096368912X657602 [DOI] [PubMed] [Google Scholar]
  • 13.Sohn HS, Heo JS, Kim HS, Choi Y, Kim HO. Duration of in vitro storage affects the key stem cell features of human bone marrow-derived mesenchymal stromal cells for clinical transplantation. Cytotherapy. 2013; 15(4): 460–466. doi: 10.1016/j.jcyt.2012.10.015 [DOI] [PubMed] [Google Scholar]
  • 14.Russell KA, Chow NH, Dukoff D, Gibson TW, LaMarre J, Betts DH, et al. Characterization and Immunomodulatory Effects of Canine Adipose Tissue- and Bone Marrow-Derived Mesenchymal Stromal Cells. PLoS One. 2016; 11(12): e0167442. doi: 10.1371/journal.pone.0167442 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Neupane M, Chang CC, Kiupel M, Yuzbasiyan-Gurkan V. Isolation and characterization of canine adipose-derived mesenchymal stem cells. Tissue Eng Part A. 2008; 14(6): 1007–1015. doi: 10.1089/tea.2007.0207 [DOI] [PubMed] [Google Scholar]
  • 16.Saeedi P, Halabian R, Imani Fooladi AA. A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies. Stem Cell Investig. 2019; 6: 34. doi: 10.21037/sci.2019.08.11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4): 315–317. doi: 10.1080/14653240600855905 [DOI] [PubMed] [Google Scholar]
  • 18.Takemitsu H, Zhao D, Yamamoto I, Harada Y, Michishita M, Arai T. Comparison of bone marrow and adipose tissue-derived canine mesenchymal stem cells. BMC Vet Res. 2012; 8: 150. doi: 10.1186/1746-6148-8-150 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Voga M, Kovač V, Majdic G. Comparison of Canine and Feline Adipose-Derived Mesenchymal Stem Cells/Medicinal Signaling Cells with Regard to Cell Surface Marker Expression, Viability, Proliferation, and Differentiation Potential. Front Vet Sci. 2021; 7: 610240. doi: 10.3389/fvets.2020.610240 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Krešić N, Šimić I, Lojkić I, Bedeković T. Canine Adipose Derived Mesenchymal Stem Cells Transcriptome Composition Alterations: A Step towards Standardizing Therapeutic. Stem Cells Int. 2017; 2017: 4176292. doi: 10.1155/2017/4176292 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Screven R, Kenyon E, Myers MJ, Yancy HF, Skasko M, Boxer L, et al. Immunophenotype and gene expression profile of mesenchymal stem cells derived from canine adipose tissue and bone marrow. Vet Immunol Immunopathol. 2014; 161(1–2): 21–31. doi: 10.1016/j.vetimm.2014.06.002 [DOI] [PubMed] [Google Scholar]
  • 22.Bauer SR. Stem Cell-based Products in Medicine: FDA Regulatory Considerations. Handbook of Stem Cells. 2004: 805–814. doi: 10.1016/B978-012436643-5/50163-2 [DOI] [Google Scholar]
  • 23.Blumberg N, Cholette JM, Pietropaoli AP, Phipps R, Spinelli SL, Eaton MP, et al. 0.9% NaCl (Normal Saline)—Perhaps not so normal after all? Transfus Apher Sci. 2018; 57(1): 127–131. doi: 10.1016/j.transci.2018.02.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Pal R, Hanwate M, Totey SM. Effect of holding time, temperature and different parenteral solutions on viability and functionality of adult bone marrow-derived mesenchymal stem cells before transplantation. J Tissue Eng Regen Med. 2008; 2(7): 436–444. doi: 10.1002/term.109 [DOI] [PubMed] [Google Scholar]
  • 25.Nofianti CE, Sari IN, Marlina Novialdi, Pawitan JA. Temporary storage solution for adipose derived mesenchymal stem cells. Stem Cell Investig. 2018; 5: 19. doi: 10.21037/sci.2018.05.04 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011; 20(8): 1297–1308. doi: 10.1089/scd.2010.0466 [DOI] [PubMed] [Google Scholar]
  • 27.Wu YD, Li M, Liao X, Li SH, Yan JX, Fan L, et al. Effects of storage culture media, temperature and duration on human adipose‑derived stem cell viability for clinical use. Mol Med Rep. 2019; 19(3): 2189–2201. doi: 10.3892/mmr.2019.9842 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Hendriks KDW, Brüggenwirth IMA, Maassen H, Gerding A, Bakker B, Porte RJ, et al. Renal temperature reduction progressively favors mitochondrial ROS production over respiration in hypothermic kidney preservation. J Transl Med. 2019; 17(1): 265. doi: 10.1186/s12967-019-2013-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Correia C, Koshkin A, Carido M, Espinha N, Šarić T, Lima PA, et al. Effective Hypothermic Storage of Human Pluripotent Stem Cell-Derived Cardiomyocytes Compatible with Global Distribution of Cells for Clinical Applications and Toxicology Testing. Stem Cells Transl Med. 2016; 5(5): 658–669. doi: 10.5966/sctm.2015-0238 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Fuller BJ, Petrenko AY, Rodriguez JV, Somov AY, Balaban CL, Guibert EE. Biopreservation of hepatocytes: current concepts on hypothermic preservation, cryopreservation, and vitrification. Cryo Letters. 2013; 34(4): 432–452. [PubMed] [Google Scholar]
  • 31.Sun W, Wang Z, Cao J, Cui H, Ma Z. Cold stress increases reactive oxygen species formation via TRPA1 activation in A549 cells. Cell Stress Chaperones. 2016; 21(2): 367–372. doi: 10.1007/s12192-015-0663-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Salahudeen AK, Huang H, Joshi M, Moore NA, Jenkins JK. Involvement of the mitochondrial pathway in cold storage and rewarming-associated apoptosis of human renal proximal tubular cells. Am J Transplant. 2003; 3(3): 273–280. doi: 10.1034/j.1600-6143.2003.00042.x [DOI] [PubMed] [Google Scholar]
  • 33.Ou J, Ball JM, Luan Y, Zhao T, Miyagishima KJ, Xu Y, et al. iPSCs from a Hibernator Provide a Platform for Studying Cold Adaptation and Its Potential Medical Applications. Cell. 2018; 173(4): 851–863.e16. doi: 10.1016/j.cell.2018.03.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Zhang L, Xue X, Yan J, Yan LY, Jin XH, Zhu XH, et al. L-proline: a highly effective cryoprotectant for mouse oocyte vitrification. Sci Rep. 2016; 6: 26326. doi: 10.1038/srep26326 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Dou M, Lu C, Sun Z, Rao W. Natural cryoprotectants combinations of l-proline and trehalose for red blood cells cryopreservation. Cryobiology. 2019; 91: 23–29. doi: 10.1016/j.cryobiol.2019.11.002 [DOI] [PubMed] [Google Scholar]
  • 36.Freimark D, Sehl C, Weber C, Hudel K, Czermak P, Hofmann N, et al. Systematic parameter optimization of a Me(2)SO- and serum-free cryopreservation protocol for human mesenchymal stem cells. Cryobiology. 2011; 63(2): 67–75. doi: 10.1016/j.cryobiol.2011.05.002 [DOI] [PubMed] [Google Scholar]
  • 37.Bhattacharya S. Cryopretectants and Their Usage in Cryopreservation Process. Bozkurt Y, editor. Cryopreservation Biotechnology in Biomedical and Biological Sciences. IntechOpen; 2018, pp. 7–19. [Google Scholar]
  • 38.Csonka LN. Physiological and genetic responses of bacteria to osmotic stress. Microbiol Rev. 1989; 53(1): 121–147. doi: 10.1128/mr.53.1.121-147.1989 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Liang X, Zhang L, Natarajan SK, Becker DF. Proline mechanisms of stress survival. Antioxid Redox Signal. 2013; 19(9): 998–1011. doi: 10.1089/ars.2012.5074 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Samuel D, Kumar TK, Ganesh G, Jayaraman G, Yang PW, Chang MM, et al. Proline inhibits aggregation during protein refolding. Protein Sci. 2000; 9(2): 344–352. doi: 10.1110/ps.9.2.344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Kaul S, Sharma SS, Mehta IK. Free radical scavenging potential of L-proline: evidence from in vitro assays. Amino Acids. 2008; 34(2): 315–320. doi: 10.1007/s00726-006-0407-x [DOI] [PubMed] [Google Scholar]
  • 42.Heidari R, Mohammadi H, Ghanbarinejad V, Ahmadi A, Ommati MM, Niknahad H, et al. Proline supplementation mitigates the early stage of liver injury in bile duct ligated rats. J Basic Clin Physiol Pharmacol. 2018; 30(1): 91–101. doi: 10.1515/jbcpp-2017-0221 [DOI] [PubMed] [Google Scholar]
  • 43.Mbongue JC, Nicholas DA, Torrez TW, Kim NS, Firek AF, Langridge WH. The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity. Vaccines (Basel). 2015; 3(3): 703–729. doi: 10.3390/vaccines3030703 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Dorronsoro A, Lang V, Ferrin I, Fernández-Rueda J, Zabaleta L, Pérez-Ruiz E, et al. Intracellular role of IL-6 in mesenchymal stromal cell immunosuppression and proliferation. Sci Rep. 2020; 10(1): 21853. doi: 10.1038/s41598-020-78864-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Bouffi C, Bony C, Courties G, Jorgensen C, Noël D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One. 2010; 5(12): e14247. doi: 10.1371/journal.pone.0014247 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Pricola KL, Kuhn NZ, Haleem-Smith H, Song Y, Tuan RS. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem. 2009; 108(3): 577–588. doi: 10.1002/jcb.22289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Maraldi T, Beretti F, Guida M, Zavatti M, De Pol A. Role of hepatocyte growth factor in the immunomodulation potential of amniotic fluid stem cells. Stem Cells Transl Med. 2015; 4(6): 539–547. doi: 10.5966/sctm.2014-0266 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Cao Z, Xie Y, Yu L, Li Y, Wang Y. Hepatocyte growth factor (HGF) and stem cell factor (SCF) maintained the stemness of human bone marrow mesenchymal stem cells (hBMSCs) during long-term expansion by preserving mitochondrial function via the PI3K/AKT, ERK1/2, and STAT3 signaling pathways. Stem Cell Res Ther. 2020; 11(1): 329. doi: 10.1186/s13287-020-01830-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011; 31(5): 986–1000. doi: 10.1161/ATVBAHA.110.207449 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Lu X, Han J, Xu X, Xu J, Liu L, Huang Y, et al. PGE2 Promotes the Migration of Mesenchymal Stem Cells through the Activation of FAK and ERK1/2 Pathway. Stem Cells Int. 2017; 2017: 8178643. doi: 10.1155/2017/8178643 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Lee BC, Kim HS, Shin TH, Kang I, Lee JY, Kim JJ, et al. PGE2 maintains self-renewal of human adult stem cells via EP2-mediated autocrine signaling and its production is regulated by cell-to-cell contact. Sci Rep. 2016; 6: 26298. doi: 10.1038/srep26298 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Goldstein RH, Sakowski S, Meeker D, Franzblau C, Polgar P. The effect of prostaglandin E2 (PGE2) on amino acid uptake and protein formation by lung fibroblasts. J Biol Chem. 1986; 261(19): 8734–8737. [PubMed] [Google Scholar]
  • 53.Ardaillou N, Nivez MP, Bellon G, Combe C, Ardaillou R. Effect of prostaglandin E2 on proline uptake and protein synthesis by cultured human mesangial cells. Kidney Int. 1990; 38(6): 1151–1158. doi: 10.1038/ki.1990.326 [DOI] [PubMed] [Google Scholar]
  • 54.Yang HM, Song WJ, Li Q, Kim SY, Kim HJ, Ryu MO, et al. Canine mesenchymal stem cells treated with TNF-α and IFN-γ enhance anti-inflammatory effects through the COX-2/PGE2 pathway. Res Vet Sci. 2018; 119: 19–26. doi: 10.1016/j.rvsc.2018.05.011 [DOI] [PubMed] [Google Scholar]
  • 55.Lin T, Pajarinen J, Nabeshima A, Lu L, Nathan K, Jämsen E, et al. Preconditioning of murine mesenchymal stem cells synergistically enhanced immunomodulation and osteogenesis. Stem Cell Res Ther. 2017; 8(1): 277. doi: 10.1186/s13287-017-0730-z [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Nazmul Haque

15 Dec 2021

PONE-D-21-31968Proline-based solution maintains cell viability and stemness of canine adipose-derived mesenchymal stem cells after hypothermic storagePLOS ONE

Dear Dr. Rungsiwiwut,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 29 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Nazmul Haque

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf  and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://aje.com/go/plos) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript

A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

A clean copy of the edited manuscript (uploaded as the new *manuscript* file

3. Thank you for stating the following financial disclosure:

“This research was funded by the Faculty of Medicine, Srinakharinwirot University (MED-GRAD-150; 511/2563 and MED-RES-200; 217/2563).”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This research was funded by the Faculty of Medicine, Srinakharinwirot University (MED-GRAD-150; 511/2563 and MED-RES-200; 217/2563).”

We note that you have provided information within the Acknowledgements Section. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This research was funded by the Faculty of Medicine, Srinakharinwirot University (MED-GRAD-150; 511/2563 and MED-RES-200; 217/2563).”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. Please upload a new copy of Figure 1A as the detail is not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

6. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript (PONE-D-21-31968_reviewer)

The manuscript demonstrates best conditions to store mesenchymal stem cells (MSCs) meant for clinical or translation application. The paper highlights proline ability to protect MSCs from apoptosis within 6hrs of hypothermic conditions. The proline protection extend to improve proliferation, and stemness ability of MSCs. The conclusion was that proline will be beneficial in case of short term transportation of MSCs.

Problems with the manuscript.

• Typos and errors are not acceptable such as “hu-man”, “col-leagues”, “sur-face”, “Live-” and others. Authors could benefit from professional editing services.

• For mitochondrial membrane potential assay authors should mention how many cells were loaded in 96 well-plate.

• For proliferation assay, authors should mention how many cells were loaded in 96 well-plate.

• Adding the figure legends between texts is confusing. Authors should add the legends at the end of manuscript after references.

• Authors should mention how many cells have been gated during flow cytometry experiments.

• Fig. 4 needs a scale bar to be added.

• Logical error when authors wrote, “when cAD-MSCs are stored in NSS and 1 mM PL-BS” It should be “when cAD-MSCs are stored in NSS or 1 mM PL-BS” since they are not combined together. Authors could use professional editing services.

• The authors claim that proline protected the mitochondria dysfunction. The present study did not support this notion. The sentence should be removed or modified into less affirm tone.

• The qPCR raw data need to be available as supplementary such as Fig.5.

• In line 494, authors should add “maybe” before “by preserving mitochondrial function”.

Minor issues

• Minor English punctuation errors.

I recommend major revision to the current version

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Bahauddeen Alrfaei

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Mar 1;17(3):e0264773. doi: 10.1371/journal.pone.0264773.r002

Author response to Decision Letter 0


19 Jan 2022

Response to Editor and Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf

and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Answer: We provided the manuscript according to PLOS ONE style requirements.

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling,and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://aje.com/go/plos) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following: The name of the colleague or the details of the professional service that edited your manuscript.

Answer: The language of our manuscript had been edited by the professional English-language editing staff at International College for Sustainability Studies of Srinakharinwirot University. The certificate of language editing is attached as a PDF.

A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

Answer: Highlighting revised manuscript is provided and uploaded as a supporting information file.

A clean copy of the edited manuscript (uploaded as the new *manuscript* file

Answer: A clean edited manuscript is provided and uploaded as the new manuscript file.

3. Thank you for stating the following financial disclosure:

“This research was funded by the Faculty of Medicine, Srinakharinwirot

University (MED-GRAD-150; 511/2563 and MED-RES-200; 217/2563).” Please state what role the funders took in the study. If the funders had no role, please state: " The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Answer: Due to the funders had no role in the present study, therefore, we state “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript”.

4. Thank you for stating the following in the Acknowledgments Section of your

manuscript: “This research was funded by the Faculty of Medicine, Srinakharinwirot University (MED-GRAD-150; 511/2563 and MED-RES-200; 217/2563).” We note that you have provided information within the Acknowledgements Section. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads

as follows: This research was funded by the Faculty of Medicine, Srinakharinwirot University (MED-GRAD-150; 511/2563 and MED-RES-200; 217/2563).

Answer: The funding statement has been removed from the Acknowledgment section.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. Please upload a new copy of

Figure 1A as the detail is not clear. Please follow the link for more information:

https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

Answer: The resolution of Figure 1A has been improved.

6. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available.

Answer: We uploaded the data set as the supporting information file (S2)

For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your studys minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter.

For a list of acceptable repositories, please see

http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data:

http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Reviewer #1: The manuscript (PONE-D-21-31968_reviewer)

The manuscript demonstrates best conditions to store mesenchymal stem cells (MSCs) meant for clinical or translation application. The paper highlights proline ability to protect MSCs from apoptosis within 6hrs of hypothermic conditions. The proline protection extends to improve proliferation, and stemness ability of MSCs. The conclusion was that proline will be beneficial in case of short-term transportation of MSCs.

Problems with the manuscript.

Typos and errors are not acceptable such as “hu-man”, “col-leagues”, “sur-face”, “Live-” and others. Authors could benefit from professional editing services.

• Answer: All typos and errors have been corrected in the revised manuscript by professional grammar editing services from the International College for Sustainability Studies, Srinakharinwirot University.

For mitochondrial membrane potential assay authors should mention how many cells were loaded in 96 well-plates.

• Answer: We added the cell number (1x105 cells/well) that was used in the mitochondrial membrane potential assay as the reviewer suggested. The cell number appear in line 168 of the revised manuscript.

For proliferation assay, authors should mention how many cells were loaded in 96 well-plates.

• Answer: We added the cell number (1x104 cells/well) that was used in the proliferation assay as the reviewer suggested. The cell number appear in line 175 of the revised manuscript.

Adding the figure legends between texts is confusing. Authors should add the legends at the end of manuscript after references.

• Answer: We moved all of the figure legends to the end of the revised manuscript (lines 639–715) as the reviewer suggested.

Authors should mention how many cells have been gated during flow cytometry experiments.

• Answer: The number of cells that were used in the flow cytometry assay was added into both the cell viability and the apoptotic/necrotic fraction assay and the expression of specific surface antigens assay, which appeared in lines 163 and 191 of the revised manuscript.

Fig. 4 needs a scale bar to be added.

• Answer: The scale bars were embedded in Fig 4 as the reviewer suggested.

Logical error when authors wrote, “when cAD-MSCs are stored in NSS and 1 mM PL-BS” It should be “when cAD-MSCs are stored in NSS or 1 mM PL-BS” since they are not combined together. Authors could use professional editing services.

• Answer: We amended the texts into “when cAD-MSCs are stored in NSS or 1 mM PL-BS” which is shown in line 675 of the revised manuscript.

The authors claim that proline protected the mitochondria dysfunction. The present study did not support this notion. The sentence should be removed or modified into less affirm tone.

• Answer: We amended the sentence “proline protected the mitochondria dysfunction” to “proline might maintain mitochondrial integrity” which is shown in line 394-395 of the revised manuscript.

The qPCR raw data need to be available as supplementary such as Fig.5.

• Answer: We added the qPCR data in supplementation S2 Table as the reviewer suggested, which appears in lines 712-715.

In line 494, authors should add “maybe” before “by preserving mitochondrial function”.

• Answer: The word "maybe" was added to the sentence before "by preserving mitochondrial function" as the reviewer suggested, and it appears in line 427 of the revised manuscript.

Minor issues

Minor English punctuation errors.

• Answer: The revised manuscript has undergone grammatical correction by professional grammar editing services from International College for Sustainability Studies, Srinakharinwirot University.

Attachment

Submitted filename: Response to the Journal requirements.docx

Decision Letter 1

Nazmul Haque

17 Feb 2022

Proline-based solution maintains cell viability and stemness of canine adipose-derived mesenchymal stem cells after hypothermic storage

PONE-D-21-31968R1

Dear Dr. Rungsiwiwut,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Nazmul Haque

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Bahauddeen Alrfaei

Acceptance letter

Nazmul Haque

21 Feb 2022

PONE-D-21-31968R1

Proline-based solution maintains cell viability and stemness of canine adipose-derived mesenchymal stem cells after hypothermic storage

Dear Dr. Rungsiwiwut:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Nazmul Haque

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Morphology of isolated canine adipose-derived mesenchymal stem cells.

    After 2 days of isolation, the adherent cells with different morphology, including fibroblast-like or epithelial-like shapes, were observed in the culture dishes. After 7 days, the cells had become more homogenous and those with a fibroblast-like shape had become dominant. The cells reached 80–90% confluence at 14 days of isolation. There was no notable difference in cell morphology among the three cell lines that had been isolated from different donors. All figures were performed at 10x magnification. Scale bars = 300 μm.

    (TIF)

    S2 Fig. Expression of specific surface antigens of non-stored and stored canine adipose-derived mesenchymal stem cells was analyzed by flow cytometer.

    The stored cells in NSS and 1 mM PL-BS highly expressed both CD44 and CD90 but were deprived of both CD34 and MHC class II. These results were not different from those of the control group.

    (TIF)

    S3 Fig. The effect of a hypothermic solution on trilineage differentiation.

    The post-stored cAD-MSCs exhibited differentiability into three lineages, including adipocytes, chondrocytes, and osteocytes. The fat droplets in adipocytes are stained red, indicating adipogenic differentiation potential. The blue color points out that chondrocytes are capable of producing proteoglycan in the extracellular matrix. The osteocytes with calcium accumulation are shown in red. Scale bars = 300 μm.

    (TIF)

    S4 Fig. The effect of a hypothermic solution on cell viability and apoptotic/necrotic fraction.

    The cAD-MSCs from two other donors decreased the number of live cells in a time-dependent manner during hypothermic conditions. However, storage of cAD-MSCs in 1 mM PL-BS for 6 hours considerably improved cell viability by decreasing early apoptosis and necrosis in comparison with storage in other concentrations of both PL-BS and NSS.

    (TIF)

    S1 Table. Sequence of primers used for evaluating the expression of immunomodulatory genes.

    (DOCX)

    S2 Table. The effect of a hypothermic solution on the expression of immunomodulatory genes.

    The gene expression results were quantified by normalization using the 2-ΔΔCT method and are shown as Log2 values of relative gene expression.

    (DOCX)

    Attachment

    Submitted filename: Response to the Journal requirements.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES